

**<PARTICULARS TO APPEAR ON THE OUTER PACKAGE>**

**{CARTON FOR PACK SIZES OF 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 30, 32, 36, 40, 42 AND 44 TABLETS}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

TermaWorm Tablets for Cats and Kittens  
230/20 mg  
Pyrantel embonate, Praziquantel

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each film-coated tablet contains Pyrantel embonate 230 mg and Praziquantel 20 mg.

**3. PHARMACEUTICAL FORM**

Film-coated tablet.

**4. PACKAGE SIZE**

2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 30, 32, 36, 40, 42, 44 tablets

**5. TARGET SPECIES**

Cats

**6. INDICATION(S)**

For the treatment of mixed infections caused by gastrointestinal roundworms and tapeworms.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

For oral administration.

1 tablet per 4 kg bodyweight.

**8. WITHDRAWAL PERIOD**

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Discard unused half tablets.

**11. SPECIAL STORAGE CONDITIONS**

Keep blister in outer carton.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read the package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only.

NFA-VPS

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd  
Loughrea  
Co. Galway  
Ireland

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 08749/4067

**17. MANUFACTURER'S BATCH NUMBER**

BN{number}

**<PARTICULARS TO APPEAR ON THE OUTER PACKAGE>**

**{CARTON FOR PACK SIZES OF 48 TABLETS, AND UPWARDS}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

TermaWorm Tablets for Cats and Kittens  
230/20 mg  
Pyrantel embonate, Praziquantel

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each film-coated tablet contains Pyrantel embonate 230 mg and Praziquantel 20 mg.

**3. PHARMACEUTICAL FORM**

Film-coated tablet.

**4. PACKAGE SIZE**

48, 50, 52, 56, 60, 64, 68, 70, 72, 76, 80, 84, 88, 92, 96, 98, 100, 104, 106, 108, 112, 116, 120, 128, 136, 140, 144, 150, 152, 160, 168, 176, 180, 184, 192, 200, 204, 206, 208, 216, 224, 232, 240, 248, 250, 280, 300, 500 or 1000 tablets

**5. TARGET SPECIES**

Cats

**6. INDICATION(S)**

For the treatment of mixed infections caused by the following gastrointestinal roundworms and tapeworms:

**Roundworms:** *Toxocara cati*, *Toxascaris leonina*,

**Tapeworms:** *Dipylidium caninum*, *Taenia taeniaeformis*, *Echinococcus multilocularis*.

## 7. METHOD AND ROUTE(S) OF ADMINISTRATION

*Dosage:* 20 mg/kg pyrantel (57.5 mg/kg pyrantel embonate) and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 4 kg bodyweight.

Body weight	tablets
1.0 - 2.0 kg	½
2.1 - 4.0 kg	1
4.1 - 6.0 kg	1 ½
6.1 - 8.0 kg	2

Single oral administration. The tablet should be given directly to the cat, but if necessary can be disguised in food.

In ascarid infestation, especially in kittens, complete elimination cannot be expected, so a risk of infection for humans can persist. Repeat treatments should, therefore, be carried out with a suitable roundworm product at 14 day intervals until 2-3 weeks after weaning.

## 8. WITHDRAWAL PERIOD

## 9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

## 10. EXPIRY DATE

EXP {month/year}

Discard unused half tablets.

## 11. SPECIAL STORAGE CONDITIONS

Keep blister in outer carton.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read the package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only.

NFA-VPS

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd  
Loughrea  
Co. Galway  
Ireland

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 08749/4067

**17. MANUFACTURER’S BATCH NUMBER**

BN {number}

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

{BLISTER FOIL TEXT}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

TermaWorm Tablets for Cats and Kittens  
230/20 mg  
Pyrantel embonate, Praziquantel

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Chanelle

**3. BATCH NUMBER**

BN {number}

**4. EXPIRY DATE**

EXP {month/year}

**5. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For Animal Treatment Only.

## PACKAGE LEAFLET

TermaWorm Tablets for Cats and Kittens  
230/20 mg

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer for batch release:  
Chanelle Pharmaceuticals Manufacturing Ltd  
Loughrea  
Co. Galway  
Ireland

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

TermaWorm Tablets for Cats and Kittens  
230/20 mg  
Pyrantel embonate, Praziquantel

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each film-coated tablet contains Pyrantel embonate 230 mg and Praziquantel 20 mg.  
A white to off white round, biconvex coated tablet with a breakline on one side and  
plain on the other side.

### 4. INDICATION(S)

For the treatment of mixed infections caused by the following gastrointestinal  
roundworms and tapeworms:

**Roundworms:** *Toxocara cati*, *Toxascaris leonina*,

**Tapeworms:** *Dipylidium caninum*, *Taenia taeniaeformis*, *Echinococcus*  
*multilocularis*.



## 5. CONTRAINDICATIONS

Do not use simultaneously with products containing piperazine.

Do not use in kittens less than 6 weeks of age.

Do not use in animals with known hypersensitivity to the active substances or to any of the excipients.

## 6. ADVERSE REACTIONS

Mild and short-lived digestive tract disorders such as excessive salivation and/or vomiting and mild and short-lived disorders of the nervous system such as loss of balance may be reported very rarely in spontaneous reports.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated )
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated )
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Cats

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

### *Dosage*

The recommended dose is: 20 mg/kg pyrantel (57.5 mg/kg pyrantel embonate) and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 4 kg bodyweight.

Body weight	tablets
1.0 - 2.0 kg	½
2.1 - 4.0 kg	1
4.1 - 6.0 kg	1 ½
6.1 - 8.0 kg	2

### *Administration and duration of treatment*

Single oral administration. The tablet should be given directly to the cat, but if necessary can be disguised in food.

In ascarid infestation, especially in kittens, complete elimination cannot be expected, so a risk of infection for humans can persist. Repeat treatments should, therefore, be carried out with a suitable roundworm product at 14 day intervals until 2-3 weeks after weaning.

## **9. ADVICE ON CORRECT ADMINISTRATION**

To ensure administration of a correct dose, body weight should be determined as accurately as possible

## **10. WITHDRAWAL PERIOD**

N/A

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Do not use this veterinary medicinal product after the expiry date which is stated on the blister and carton.

The expiry date refers to the last day of that month.

Discard unused half tablets.

Keep blister in outer carton.

## **12. SPECIAL WARNING(S)**

### **Special precautions for use in animals**

Do not use during pregnancy but may be used during lactation.

After doses higher than 5 times the recommended dose, signs of intolerance such as vomiting have been observed.

Parasitic resistance to a certain class of anthelmintics can occur after frequent and repeated use of an anthelmintic from this class.

Fleas serve as intermediate hosts for one common type of tapeworm – *Dipylidium*

*caninum*. Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc. is undertaken.

**Special precautions to be taken by the person administering the veterinary medicinal product to animals**

In case of accidental ingestion, seek medical advice and show the package leaflet to the physician.

In the interests of good hygiene, persons administering the tablets directly to a cat or adding them to the cat's food should wash their hands afterwards.

**Other precautions**

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

For animal treatment only.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

June 2021

**15. OTHER INFORMATION**

2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 30, 32, 36, 40, 42, 44, 48, 50, 52, 56, 60, 64, 68, 70, 72, 76, 80, 84, 88, 92, 96, 98, 100, 104, 106, 108, 112, 116, 120, 128, 136, 140, 144, 150, 152, 160, 168, 176, 180, 184, 192, 200, 204, 206, 208, 216, 224, 232, 240, 248, 250, 280, 300, 500 or 1000 tablets.

Not all pack sizes may be marketed.

NFA-VPS

Approved: 18/06/21

D. Austin